130 related articles for article (PubMed ID: 11932873)
1. Experience with etanercept in an academic medical center: are infection rates increased?
Phillips K; Husni ME; Karlson EW; Coblyn JS
Arthritis Rheum; 2002 Feb; 47(1):17-21. PubMed ID: 11932873
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
[TBL] [Abstract][Full Text] [Related]
3. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
Kremer JM; Weinblatt ME; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Jackson CG; Atkins KM; Feng A; Burge DJ
Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815
[TBL] [Abstract][Full Text] [Related]
4. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
Culy CR; Keating GM
Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
[TBL] [Abstract][Full Text] [Related]
5. Etanercept: new preparation. Useful after methotrexate failure in inflammatory rheumatism.
Prescrire Int; 2003 Aug; 12(66):127-32. PubMed ID: 12906020
[TBL] [Abstract][Full Text] [Related]
6. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.
Moreland LW; Weinblatt ME; Keystone EC; Kremer JM; Martin RW; Schiff MH; Whitmore JB; White BW
J Rheumatol; 2006 May; 33(5):854-61. PubMed ID: 16541481
[TBL] [Abstract][Full Text] [Related]
7. [Pharmaceutical care of patients with rheumatoid and psoriatic arthritis receiving etanercept].
Romero Crespo I; Antón Torres R; Borrás Blasco J; Navarro Ruiz A
Farm Hosp; 2005; 29(3):171-6. PubMed ID: 16013943
[TBL] [Abstract][Full Text] [Related]
8. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
9. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.
Fleischmann R; Iqbal I
Drugs Aging; 2007; 24(3):239-54. PubMed ID: 17362051
[TBL] [Abstract][Full Text] [Related]
10. [Etanercept].
Takeuchi T; Amano K
Nihon Rinsho; 2002 Dec; 60(12):2390-6. PubMed ID: 12510367
[TBL] [Abstract][Full Text] [Related]
11. [Etanercept].
Sparsa A
Ann Dermatol Venereol; 2005 Nov; 132(11 Pt 1):861-76. PubMed ID: 16327716
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
[TBL] [Abstract][Full Text] [Related]
13. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
[TBL] [Abstract][Full Text] [Related]
14. Etanercept: therapeutic use in patients with rheumatoid arthritis.
Garrison L; McDonnell ND
Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I65-9. PubMed ID: 10577976
[TBL] [Abstract][Full Text] [Related]
15. Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries.
Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; McCroskery P; Baumgartner SW; Markenson JA
J Rheumatol; 2011 Jan; 38(1):21-8. PubMed ID: 20952478
[TBL] [Abstract][Full Text] [Related]
16. Etanercept for the treatment of rheumatoid arthritis.
Blumenauer B; Judd M; Cranney A; Burls A; Coyle D; Hochberg M; Tugwell P; Wells G
Cochrane Database Syst Rev; 2003; (4):CD004525. PubMed ID: 14584021
[TBL] [Abstract][Full Text] [Related]
17. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
18. Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment.
Levälampi T; Korpela M; Vuolteenaho K; Moilanen E
Rheumatol Int; 2008 Jan; 28(3):261-9. PubMed ID: 17846778
[TBL] [Abstract][Full Text] [Related]
19. Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial.
Ruwaard J; L' Ami MJ; Kneepkens EL; Krieckaert C; Nurmohamed MT; Hooijberg F; van Kuijk A; van Denderen JC; Burgemeister L; Rispens T; Boers M; Wolbink GJ
Scand J Rheumatol; 2023 Mar; 52(2):129-136. PubMed ID: 35234569
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.
Gottlieb AB; Gordon K; Giannini EH; Mease P; Li J; Chon Y; Maddox J; Weng HH; Wajdula J; Lin SL; Baumgartner SW
J Drugs Dermatol; 2011 Mar; 10(3):289-300. PubMed ID: 21369647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
